Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study.
The underlying pathology of arsenic-related cardiovascular disease (CVD) is unknown. Few studies have evaluated pathways through thrombosis and inflammation for arsenic-related CVD, especially at low-moderate arsenic exposure levels (<100 μg/L in drinking water). We evaluated the association of c...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0182435&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850230037429616640 |
|---|---|
| author | Katherine A Moon Ana Navas-Acien Maria Grau-Pérez Kevin A Francesconi Walter Goessler Eliseo Guallar Jason G Umans Lyle G Best Jonathan D Newman |
| author_facet | Katherine A Moon Ana Navas-Acien Maria Grau-Pérez Kevin A Francesconi Walter Goessler Eliseo Guallar Jason G Umans Lyle G Best Jonathan D Newman |
| author_sort | Katherine A Moon |
| collection | DOAJ |
| description | The underlying pathology of arsenic-related cardiovascular disease (CVD) is unknown. Few studies have evaluated pathways through thrombosis and inflammation for arsenic-related CVD, especially at low-moderate arsenic exposure levels (<100 μg/L in drinking water). We evaluated the association of chronic low-moderate arsenic exposure, measured as the sum of inorganic and methylated arsenic species in urine (ΣAs), with plasma biomarkers of thrombosis and inflammation in American Indian adults (45-74 years) in the Strong Heart Study. We evaluated the cross-sectional and longitudinal associations between baseline ΣAs with fibrinogen at three visits (baseline, 1989-91; Visit 2, 1993-95, Visit 3, 1998-99) using mixed models and the associations between baseline ΣAs and Visit 2 plasminogen activator inhibitor-1 (PAI-1) and high sensitivity C-reactive protein (hsCRP) using linear regression. Median (interquartile range) concentrations of baseline ΣAs and fibrinogen, and Visit 2 hsCRP and PAI-1 were 8.4 (5.1, 14.3) μg/g creatinine, 346 (304, 393) mg/dL, 44 (30, 67) mg/L, and 3.8 (2.0, 7.0) ng/mL, respectively. Comparing the difference between the 75th and the 25th percentile of ΣAs (14.3 vs. 5.1 μg/g creatinine), ΣAs was positively associated with baseline fibrinogen among those with diabetes (adjusted geometric mean ratio (GMR): 1.05, 95% CI: 1.02, 1.07) not associated among those without diabetes (GMR: 1.01, 95% CI: 0.99, 1.02) (p-interaction for diabetes = 0.014), inversely associated with PAI-1 (GMR: 0.94, 95% CI: 0.90, 0.99), and not associated with hsCRP (GMR: 1.00, 95% CI: 0.93, 1.08). We found no evidence for an association between baseline ΣAs and annual change in fibrinogen over follow-up (p-interaction = 0.28 and 0.12 for diabetes and non-diabetes, respectively). Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1. Further research should evaluate the role of prothrombotic factors in arsenic-related cardiovascular disease. |
| format | Article |
| id | doaj-art-dfdf7bac375540fa91efe2a4808bb2d6 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-dfdf7bac375540fa91efe2a4808bb2d62025-08-20T02:03:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01128e018243510.1371/journal.pone.0182435Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study.Katherine A MoonAna Navas-AcienMaria Grau-PérezKevin A FrancesconiWalter GoesslerEliseo GuallarJason G UmansLyle G BestJonathan D NewmanThe underlying pathology of arsenic-related cardiovascular disease (CVD) is unknown. Few studies have evaluated pathways through thrombosis and inflammation for arsenic-related CVD, especially at low-moderate arsenic exposure levels (<100 μg/L in drinking water). We evaluated the association of chronic low-moderate arsenic exposure, measured as the sum of inorganic and methylated arsenic species in urine (ΣAs), with plasma biomarkers of thrombosis and inflammation in American Indian adults (45-74 years) in the Strong Heart Study. We evaluated the cross-sectional and longitudinal associations between baseline ΣAs with fibrinogen at three visits (baseline, 1989-91; Visit 2, 1993-95, Visit 3, 1998-99) using mixed models and the associations between baseline ΣAs and Visit 2 plasminogen activator inhibitor-1 (PAI-1) and high sensitivity C-reactive protein (hsCRP) using linear regression. Median (interquartile range) concentrations of baseline ΣAs and fibrinogen, and Visit 2 hsCRP and PAI-1 were 8.4 (5.1, 14.3) μg/g creatinine, 346 (304, 393) mg/dL, 44 (30, 67) mg/L, and 3.8 (2.0, 7.0) ng/mL, respectively. Comparing the difference between the 75th and the 25th percentile of ΣAs (14.3 vs. 5.1 μg/g creatinine), ΣAs was positively associated with baseline fibrinogen among those with diabetes (adjusted geometric mean ratio (GMR): 1.05, 95% CI: 1.02, 1.07) not associated among those without diabetes (GMR: 1.01, 95% CI: 0.99, 1.02) (p-interaction for diabetes = 0.014), inversely associated with PAI-1 (GMR: 0.94, 95% CI: 0.90, 0.99), and not associated with hsCRP (GMR: 1.00, 95% CI: 0.93, 1.08). We found no evidence for an association between baseline ΣAs and annual change in fibrinogen over follow-up (p-interaction = 0.28 and 0.12 for diabetes and non-diabetes, respectively). Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1. Further research should evaluate the role of prothrombotic factors in arsenic-related cardiovascular disease.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0182435&type=printable |
| spellingShingle | Katherine A Moon Ana Navas-Acien Maria Grau-Pérez Kevin A Francesconi Walter Goessler Eliseo Guallar Jason G Umans Lyle G Best Jonathan D Newman Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. PLoS ONE |
| title | Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. |
| title_full | Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. |
| title_fullStr | Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. |
| title_full_unstemmed | Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. |
| title_short | Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study. |
| title_sort | low moderate urine arsenic and biomarkers of thrombosis and inflammation in the strong heart study |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0182435&type=printable |
| work_keys_str_mv | AT katherineamoon lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT ananavasacien lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT mariagrauperez lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT kevinafrancesconi lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT waltergoessler lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT eliseoguallar lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT jasongumans lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT lylegbest lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy AT jonathandnewman lowmoderateurinearsenicandbiomarkersofthrombosisandinflammationinthestrongheartstudy |